Kallyope

Kallyope is a New York City-based company focused on big health challenges, particularly migraine. It leverages unique insights into neural signaling pathways to develop innovative medicines. Its lead asset, Elismetrep, is in Phase 3 for the acute treatment of migraine. The company was founded by world-leading neuroscientists and is staffed by experienced drug developers.

Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. The company is based in New York City and focuses on developing innovative medicines for migraine.

1. Kallyope | Focusing on Big Health Challenges That Matter
2. About Us | Kallyope